Complement C5 Inhibitory Humanized Recycling Monoclonal Antibody (rg-6107 ) Uses, Dosage, Side Effects and more
Complement C5 Inhibitory Humanized Recycling Monoclonal Antibody (rg-6107 ) is under investigation in clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Complement C5 Inhibitory Humanized Recycling Monoclonal Antibody (rg-6107 ) in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria).
| Trade Name | Complement C5 Inhibitory Humanized Recycling Monoclonal Antibody (rg-6107 ) |
| Generic | Crovalimab |
| Crovalimab Other Names | Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107 ), Crovalimab, Immunoglobulin g1, anti-(human complement c5)(humanized ro7112689 heavy chain), disulfide with humanized ro7112689 light chain, dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
